{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:05:15Z","timestamp":1792209915333,"version":"4.4.0"},"reference-count":101,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressively debilitating, rare disease associated with high mortality. ATTR-CM occurs when TTR amyloid protein builds up in the myocardium along with different organs, most commonly the peripheral and the autonomic nervous systems. Managing the cardiac complications with standard heart failure medications is difficult due to the challenge to maintain a balance between the high filling pressure associated with restricted ventricular volume and the low cardiac output. To date, tafamidis is the only agent approved for ATTR-CM treatment. Besides, several agents, including green tea, tolcapone, and diflunisal, are used off-label in ATTR-CM patients. Novel therapies using RNA interference also offer clinical promise. Patisiran and inotersen are currently approved for ATTR-polyneuropathy of hereditary origin and are under investigation for ATTR-CM. Monoclonal antibodies in the early development phases carry hope for amyloid deposit clearance. Despite several drug candidates in the clinical development pipeline, the small ATTR-CM patient population raises several challenges. This review describes current and future therapies for ATTR-CM and sheds light on the clinical development hurdles facing them.<\/jats:p>","DOI":"10.3390\/jcm11082148","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T21:15:35Z","timestamp":1649798135000},"page":"2148","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Treatment of Transthyretin Amyloid Cardiomyopathy: The Current Options, the Future, and the Challenges"],"prefix":"10.3390","volume":"11","author":[{"given":"Carsten","family":"Tsch\u00f6pe","sequence":"first","affiliation":[{"name":"Berlin Institute of Health (BIH) Center for Regenerative Therapies (BCRT), Campus Virchow Clinic, Charit\u00e9\u2013University Medicine Berlin, D-13353 Berlin, Germany"},{"name":"German Centre for Cardiovascular Research (DZHK), Partner Site Berlin, D-13353 Berlin, Germany"},{"name":"Department of Cardiology, Campus Virchow Klinikum, Charit\u00e9\u2013University Medicine Berlin, D-13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4864-7685","authenticated-orcid":false,"given":"Ahmed","family":"Elsanhoury","sequence":"additional","affiliation":[{"name":"Berlin Institute of Health (BIH) Center for Regenerative Therapies (BCRT), Campus Virchow Clinic, Charit\u00e9\u2013University Medicine Berlin, D-13353 Berlin, Germany"},{"name":"German Centre for Cardiovascular Research (DZHK), Partner Site Berlin, D-13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/nrneph.2013.171","article-title":"Pathophysiology and treatment of systemic amyloidosis","volume":"9","author":"Gillmore","year":"2013","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3949\/ccjm.84.s3.02","article-title":"Cardiac amyloidosis: An update on diagnosis and treatment","volume":"84","author":"Donnelly","year":"2017","journal-title":"Cleve Clin. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1136\/jcp.2004.017293","article-title":"Amyloid in the cardiovascular system: A review","volume":"58","author":"Kholova","year":"2005","journal-title":"J. Clin. Pathol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443200","article-title":"Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy","volume":"135","author":"Muchtar","year":"2016","journal-title":"Acta Haematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/iub.340","article-title":"Aboard transthyretin: From transport to cleavage","volume":"62","author":"Liz","year":"2010","journal-title":"IUBMB Life"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.carpath.2015.07.008","article-title":"Cardiac amyloidosis: Pathology, nomenclature, and typing","volume":"24","author":"Maleszewski","year":"2015","journal-title":"Cardiovasc. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0065-3233(08)60321-6","article-title":"Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid","volume":"50","author":"Kelly","year":"1997","journal-title":"Adv. Protein Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1212\/WNL.36.7.900","article-title":"Transthyretin: A choroid plexus-specific transport protein in human brain. The 1986 S. Weir Mitchell award","volume":"36","author":"Herbert","year":"1986","journal-title":"Neurology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Nativi-Nicolau, J.N., Karam, C., Khella, S., and Maurer, M.S. (2021). Screening for ATTR amyloidosis in the clinic: Overlapping disorders, misdiagnosis, and multiorgan awareness. Heart Fail. Rev., 1\u20139.","DOI":"10.1007\/s10741-021-10080-2"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses: Disease profiles and clinical courses of the 3 main types","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.jacc.2018.07.092","article-title":"Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release","volume":"72","author":"Sperry","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin-related hereditary amyloidosis for clinicians","volume":"8","author":"Ando","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/gim.2016.200","article-title":"Transthyretin V122I (pV142I)* cardiac amyloidosis: An age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans","volume":"19","author":"Buxbaum","year":"2017","journal-title":"Genet. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis","volume":"126","author":"Ruberg","year":"2012","journal-title":"Circulation"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1073\/pnas.87.7.2843","article-title":"Fibril in senile systemic amyloidosis is derived from normal transthyretin","volume":"87","author":"Westermark","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac. Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jns.12153","article-title":"\u201cRed-flag\u201d symptom clusters in transthyretin familial amyloid polyneuropathy","volume":"21","author":"Obici","year":"2016","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/HCO.0000000000000547","article-title":"Amyloidosis cardiomyopathy: Update in the diagnosis and treatment of the most common types","volume":"33","author":"Maurer","year":"2018","journal-title":"Curr. Opin. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","article-title":"Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice","volume":"7","author":"Witteles","year":"2019","journal-title":"JACC Heart Fail."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13023-021-01706-7","article-title":"Patient and family experience with transthyretin amyloid cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN) amyloidosis: Results of two focus groups","volume":"16","author":"Rintell","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/ajt.16216","article-title":"Transthyretin amyloidosis with cardiomyopathy after domino liver transplantation: Results of a cross-sectional study","volume":"21","author":"Baliellas","year":"2021","journal-title":"Am. J. Transplant."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10741-014-9462-7","article-title":"Natural history and therapy of TTR-cardiac amyloidosis: Emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs","volume":"20","author":"Drachman","year":"2015","journal-title":"Heart Fail. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"989","DOI":"10.7326\/0003-4819-55-6-989","article-title":"Cardiac amyloidosis. Two cases with digitalis sensitivity","volume":"55","author":"Cassidy","year":"1961","journal-title":"Ann. Intern. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10286-019-00623-x","article-title":"Orthostatic hypotension in hereditary transthyretin amyloidosis: Epidemiology, diagnosis and management","volume":"29","author":"Palma","year":"2019","journal-title":"Clin. Auton. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1177\/2047487320920756","article-title":"Management of complications of cardiac amyloidosis: 10 questions and answers","volume":"28","author":"Aimo","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/13506129.2020.1810010","article-title":"Anticoagulation with warfarin compared to novel oral anticoagulants for atrial fibrillation in adults with transthyretin cardiac amyloidosis: Comparison of thromboembolic events and major bleeding","volume":"28","author":"Mitrani","year":"2021","journal-title":"Amyloid"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2217\/ahe.13.10","article-title":"Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center","volume":"9","author":"Givens","year":"2013","journal-title":"Aging Health"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e000098","DOI":"10.1161\/JAHA.113.000098","article-title":"Senile systemic amyloidosis: Clinical features at presentation and outcome","volume":"2","author":"Pinney","year":"2013","journal-title":"J. Am. Heart Assoc."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.hrthm.2013.10.026","article-title":"Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis","volume":"11","author":"Varr","year":"2014","journal-title":"Heart Rhythm."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.jacc.2019.09.056","article-title":"Aortic Stenosis and Cardiac Amyloidosis: JACC Review Topic of the Week","volume":"74","author":"Ternacle","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/j.phytochem.2006.06.020","article-title":"Epigallocatechin-3-gallate (EGCG): Chemical and biomedical perspectives","volume":"67","author":"Nagle","year":"2006","journal-title":"Phytochemistry"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00392-012-0463-z","article-title":"Green tea halts progression of cardiac transthyretin amyloidosis: An observational report","volume":"101","author":"Kristen","year":"2012","journal-title":"Clin. Res. Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s11739-018-1887-x","article-title":"Epigallocatechin-3-gallate tolerability and impact on survival in a cohort of patients with transthyretin-related cardiac amyloidosis. A single-center retrospective study","volume":"13","author":"Cappelli","year":"2018","journal-title":"Intern. Emerg. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","article-title":"Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative?","volume":"99","author":"Ericzon","year":"2015","journal-title":"Transplantation"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1212\/WNL.0b013e3181ea15d4","article-title":"Progression of transthyretin amyloid neuropathy after liver transplantation","volume":"75","author":"Liepnieks","year":"2010","journal-title":"Neurology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/lt.21996","article-title":"Liver transplantation and combined liver-heart transplantation in patients with familial amyloid polyneuropathy: A single-center experience","volume":"16","author":"Barreiros","year":"2010","journal-title":"Liver Transpl."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.recesp.2017.05.018","article-title":"Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis","volume":"70","author":"Sainz","year":"2017","journal-title":"Prog. Hope Rev. Esp. Cardiol. Engl. Ed."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2174\/156800705774322076","article-title":"Small transthyretin (TTR) ligands as possible therapeutic agents in TTR amyloidoses","volume":"4","author":"Almeida","year":"2005","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"14192","DOI":"10.1074\/jbc.RA118.003990","article-title":"Plasminogen activation triggers transthyretin amyloidogenesis in vitro","volume":"293","author":"Mangione","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1042\/BJ20040011","article-title":"Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative","volume":"381","author":"Almeida","year":"2004","journal-title":"Biochem. J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/13506129.2019.1597702","article-title":"Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: Proof-of-concept study","volume":"26","author":"Gamez","year":"2019","journal-title":"Amyloid"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1023\/A:1018852223902","article-title":"Effects of tolcapone, a catechol-O-methyltransferase inhibitor, and Sinemet on intestinal electrolyte and fluid transport in conscious dogs","volume":"43","author":"Larsen","year":"1998","journal-title":"Dig. Dis. Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.2165\/00003495-200059060-00004","article-title":"Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson\u2019s disease","volume":"59","author":"Kaakkola","year":"2000","journal-title":"Drugs"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/FPC.0b013e3283349e84","article-title":"Cytochrome P450 2C9-CYP2C9","volume":"20","author":"Marsh","year":"2010","journal-title":"Pharm. Genom."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: A randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/13506129.2019.1593133","article-title":"The Swedish open-label diflunisal trial (DFNS01) on hereditary transthyretin amyloidosis and the impact of amyloid fibril composition","volume":"26","author":"Wixner","year":"2019","journal-title":"Amyloid"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Siddiqi, O.K., Mints, Y.Y., Berk, J.L., Connors, L., Doros, G., Gopal, D.M., Kataria, S., Lohrmann, G., Pipilas, A.R., and Ruberg, F.L. (2022). Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: The Boston University Amyloidosis Center experience. Amyloid, 1\u20138.","DOI":"10.1080\/13506129.2021.2000388"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.cardfail.2019.11.024","article-title":"Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis","volume":"26","author":"Lohrmann","year":"2020","journal-title":"J. Card. Fail."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1002\/anie.200351179","article-title":"Benzoxazoles as transthyretin amyloid fibril inhibitors: Synthesis, evaluation, and mechanism of action","volume":"42","author":"Razavi","year":"2003","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1060028019888489","article-title":"Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy","volume":"54","author":"Park","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1111\/ene.12225","article-title":"Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy","volume":"20","author":"Lozeron","year":"2013","journal-title":"Eur. J. Neurol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s12265-013-9512-x","article-title":"Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis","volume":"6","author":"Merlini","year":"2013","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1161\/CIRCHEARTFAILURE.113.000890","article-title":"Tafamidis in transthyretin amyloid cardiomyopathy: Effects on transthyretin stabilization and clinical outcomes","volume":"8","author":"Maurer","year":"2015","journal-title":"Circ. Heart Fail."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/ejhf.2028","article-title":"Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis","volume":"23","author":"Kharoubi","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/13506129.2015.1063485","article-title":"Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy)","volume":"22","author":"Cho","year":"2015","journal-title":"Amyloid"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/cpdd.789","article-title":"The Bioequivalence of Tafamidis 61-mg Free Acid Capsules and Tafamidis Meglumine 4 x 20-mg Capsules in Healthy Volunteers","volume":"9","author":"Lockwood","year":"2020","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ejhf.2027","article-title":"Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study","volume":"23","author":"Damy","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Rapezzi, C., Kristen, A., Gundapaneni, B., Sultan, M., and Hanna, M. (2020). Benefits of tafamidis in patients with advanced transthyretin amyloid cardiomyopathy. Eur. Heart J., 41.","DOI":"10.1093\/ehjci\/ehaa946.2115"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"ehab724.0829","DOI":"10.1093\/eurheartj\/ehab724.0829","article-title":"Estimating treatment effect of tafamidis on hospitalisation in NYHA class III ATTR-CM patients in the presence of death using principal stratification","volume":"42","author":"Li","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy","volume":"74","author":"Judge","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/13506129.2020.1808783","article-title":"Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma","volume":"28","author":"Nelson","year":"2021","journal-title":"Amyloid"},{"key":"ref_68","unstructured":"(2022, March 21). Trial of Acoramidis for Transthyretin Amyloid Cardiomyopathy Misses Primary Endpoint. Available online: https:\/\/www.healio.com\/news\/cardiology\/20211228\/trial-of-acoramidis-for-transthyretin-amyloid-cardiomyopathy-misses-primary-endpoint."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"8274","DOI":"10.1021\/acs.jmedchem.9b01037","article-title":"Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes","volume":"62","author":"Corazza","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41598-017-00338-x","article-title":"Inhibition of the mechano-enzymatic amyloidogenesis of transthyretin: Role of ligand affinity, binding cooperativity and occupancy of the inner channel","volume":"7","author":"Verona","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/ctr.12193","article-title":"Modified body mass index and time interval between diagnosis and operation affect survival after liver transplantation for hereditary amyloidosis: A single-center analysis","volume":"27","author":"Franz","year":"2013","journal-title":"Clin. Transplant."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","article-title":"RNA-Targeted Therapeutics","volume":"27","author":"Crooke","year":"2018","journal-title":"Cell Metab."},{"key":"ref_73","first-page":"267","article-title":"Update on the clinical utility of an RNA interference-based treatment: Focus on Patisiran","volume":"10","author":"Rizk","year":"2017","journal-title":"Pharmgenom. Pers. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.addr.2020.07.022","article-title":"Recent advances in siRNA delivery mediated by lipid-based nanoparticles","volume":"154\u2013155","author":"Yonezawa","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","article-title":"Reduction in CMR Derived Extracellular Volume With Patisiran Indicates Cardiac Amyloid Regression","volume":"14","author":"Fontana","year":"2021","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/13506129.2019.1685487","article-title":"Inotersen therapy of transthyretin amyloid cardiomyopathy","volume":"27","author":"Dasgupta","year":"2020","journal-title":"Amyloid"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ymthe.2016.10.019","article-title":"Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate","volume":"25","author":"Zimmermann","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10557-019-06919-4","article-title":"Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)","volume":"34","author":"Judge","year":"2020","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: State of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal. Transduct. Target. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/cpt.1974","article-title":"Single-Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N-acetylgalactosamine-Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects","volume":"109","author":"Habtemariam","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_84","unstructured":"Alnylam Pharmaceuticals (2022, January 21). Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy. Available online: https:\/\/investors.alnylam.com\/press-release?id=26396."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40120-021-00235-6","article-title":"Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy","volume":"10","author":"Coelho","year":"2021","journal-title":"Neurol. Ther."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Ledford, H. (2021). Landmark CRISPR trial shows promise against deadly disease. Nature.","DOI":"10.1038\/d41586-021-01776-4"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1128\/AAC.00594-16","article-title":"rRNA Binding Sites and the Molecular Mechanism of Action of the Tetracyclines","volume":"60","author":"Chukwudi","year":"2016","journal-title":"Antimicrob. Agents Chemother"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"635760","DOI":"10.3389\/fnagi.2021.635760","article-title":"Doxycycline Interferes With Tau Aggregation and Reduces Its Neuronal Toxicity","volume":"13","author":"Medina","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1479-5876-8-74","article-title":"Synergy of combined doxycycline\/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: Studies in FAP mouse models","volume":"8","author":"Cardoso","year":"2010","journal-title":"J. Transl. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/13506129.2012.678508","article-title":"Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: A phase II study","volume":"19","author":"Obici","year":"2012","journal-title":"Amyloid"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/13506129.2016.1269739","article-title":"Effect of doxycycline and ursodeoxycholic acid on transthyretin amyloidosis","volume":"24","author":"Wixner","year":"2017","journal-title":"Amyloid"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/13506129.2016.1148025","article-title":"Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin","volume":"23","author":"Higaki","year":"2016","journal-title":"Amyloid"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1038\/s41467-021-23274-x","article-title":"A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells","volume":"12","author":"Michalon","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1177\/10600280211000351","article-title":"Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies","volume":"55","author":"Yadav","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.stem.2016.08.012","article-title":"Overcoming Challenges Facing Advanced Therapies in the EU Market","volume":"19","author":"Elsanhoury","year":"2016","journal-title":"Cell Stem Cell"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jchf.2020.09.011","article-title":"Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT","volume":"9","author":"Rapezzi","year":"2021","journal-title":"JACC Heart Fail."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/13506129.2018.1479249","article-title":"Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary ATTRV30M (p.TTRV50M) amyloidosis patients","volume":"25","author":"Monteiro","year":"2018","journal-title":"Amyloid"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s42466-021-00155-8","article-title":"Are we creating a new phenotype? Physiological barriers and ethical considerations in the treatment of hereditary transthyretin-amyloidosis","volume":"3","author":"Dohrn","year":"2021","journal-title":"Neurol. Res. Pract."},{"key":"ref_101","first-page":"CD012395","article-title":"Pharmacological treatment for familial amyloid polyneuropathy","volume":"4","author":"Magrinelli","year":"2020","journal-title":"Cochrane Database Syst. Rev."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/8\/2148\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:52:26Z","timestamp":1760136746000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/8\/2148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,12]]},"references-count":101,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["jcm11082148"],"URL":"https:\/\/doi.org\/10.3390\/jcm11082148","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,12]]}}}